These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

276 related articles for article (PubMed ID: 22098228)

  • 1. Treating chronic lymphocytic leukemia with thalidomide and lenalidomide.
    Giannopoulos K; Mertens D; Stilgenbauer S
    Expert Opin Pharmacother; 2011 Dec; 12(18):2857-64. PubMed ID: 22098228
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lenalidomide in the treatment of chronic lymphocytic leukemia.
    Gentile M; Recchia AG; Vigna E; Mazzone C; Lucia E; Gigliotti V; Bossio S; Madeo A; Morabito L; Servillo P; Franzese S; Caruso N; De Stefano L; Bisconte MG; Gentile C; Morabito F
    Expert Opin Investig Drugs; 2011 Feb; 20(2):273-86. PubMed ID: 21214505
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lenalidomide in lymphomas and chronic lymphocytic leukemia.
    Wiernik PH
    Expert Opin Pharmacother; 2013 Mar; 14(4):475-88. PubMed ID: 23356486
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lenalidomide in CLL: what is the optimal dose?
    Wendtner CM
    Clin Adv Hematol Oncol; 2011 Mar; 9(3):220-4. PubMed ID: 21475128
    [No Abstract]   [Full Text] [Related]  

  • 5. Lenalidomide in the treatment of chronic lymphocytic leukemia.
    Itchaki G; Brown JR
    Expert Opin Investig Drugs; 2017 May; 26(5):633-650. PubMed ID: 28388253
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The emerging role of lenalidomide in the management of mantle cell lymphoma (MCL).
    Dawar R; Hernandez-Ilizaliturri F
    Best Pract Res Clin Haematol; 2012 Jun; 25(2):185-90. PubMed ID: 22687454
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Management of patients with chronic lymphocytic leukemia treated with lenalidomide.
    Miller KC; Musial L; Whitworth A; Chanan-Khan A
    Clin J Oncol Nurs; 2010 Aug; 14(4):491-9. PubMed ID: 20682505
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lenalidomide alone and in combination for chronic lymphocytic leukemia.
    Chen CI
    Curr Hematol Malig Rep; 2013 Mar; 8(1):7-13. PubMed ID: 23254517
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lenalidomide and chronic lymphocytic leukemia.
    González-Rodríguez AP; Payer AR; Acebes-Huerta A; Huergo-Zapico L; Villa-Alvarez M; Gonzalez-García E; Gonzalez S
    Biomed Res Int; 2013; 2013():932010. PubMed ID: 24163824
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lenalidomide for the treatment of B-cell malignancies.
    Chanan-Khan AA; Cheson BD
    J Clin Oncol; 2008 Mar; 26(9):1544-52. PubMed ID: 18285605
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tumor flare reaction associated with lenalidomide treatment in patients with chronic lymphocytic leukemia predicts clinical response.
    Chanan-Khan A; Miller KC; Lawrence D; Padmanabhan S; Miller A; Hernandez-Illatazurri F; Czuczman MS; Wallace PK; Zeldis JB; Lee K
    Cancer; 2011 May; 117(10):2127-35. PubMed ID: 21523725
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunomodulatory drugs in chronic lymphocytic leukemia: a new treatment paradigm.
    Molica S
    Leuk Lymphoma; 2007 May; 48(5):866-9. PubMed ID: 17487728
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Novel agents for chronic lymphocytic leukemia.
    Wu M; Akinleye A; Zhu X
    J Hematol Oncol; 2013 May; 6():36. PubMed ID: 23680477
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-term molecular remission with lenalidomide treatment of relapsed chronic lymphocytic leukemia.
    Spina F; Rezzonico F; Farina L; Corradini P
    Eur J Haematol; 2013 Apr; 90(4):340-4. PubMed ID: 23281656
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lenalidomide in chronic lymphocytic leukemia: the present and future in the era of tyrosine kinase inhibitors.
    Maffei R; Colaci E; Fiorcari S; Martinelli S; Potenza L; Luppi M; Marasca R
    Crit Rev Oncol Hematol; 2016 Jan; 97():291-302. PubMed ID: 26454471
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lenalidomide can be highly effective in chronic lymphocytic leukaemia despite T-cell depletion and deletion of chromosome 17p.
    Arumainathan A; Kalakonda N; Pettitt AR
    Eur J Haematol; 2011 Oct; 87(4):372-5. PubMed ID: 21679253
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lenalidomide and its role in the management of multiple myeloma.
    Falco P; Cavallo F; Larocca A; Liberati AM; Musto P; Boccadoro M; Palumbo A
    Expert Rev Anticancer Ther; 2008 Jun; 8(6):865-74. PubMed ID: 18533796
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Final results of a multicenter phase 1 study of lenalidomide in patients with relapsed or refractory chronic lymphocytic leukemia.
    Wendtner CM; Hillmen P; Mahadevan D; Bühler A; Uharek L; Coutré S; Frankfurt O; Bloor A; Bosch F; Furman RR; Kimby E; Gribben JG; Gobbi M; Dreisbach L; Hurd DD; Sekeres MA; Ferrajoli A; Shah S; Zhang J; Moutouh-de Parseval L; Hallek M; Heerema NA; Stilgenbauer S; Chanan-Khan AA
    Leuk Lymphoma; 2012 Mar; 53(3):417-23. PubMed ID: 21879809
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Single-agent lenalidomide in the treatment of previously untreated chronic lymphocytic leukemia.
    Chen CI; Bergsagel PL; Paul H; Xu W; Lau A; Dave N; Kukreti V; Wei E; Leung-Hagesteijn C; Li ZH; Brandwein J; Pantoja M; Johnston J; Gibson S; Hernandez T; Spaner D; Trudel S
    J Clin Oncol; 2011 Mar; 29(9):1175-81. PubMed ID: 21189385
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Thalidomide and lenalidomide as new therapeutics for the treatment of chronic lymphocytic leukemia.
    Awan FT; Johnson AJ; Lapalombella R; Hu W; Lucas M; Fischer B; Byrd JC
    Leuk Lymphoma; 2010 Jan; 51(1):27-38. PubMed ID: 20055657
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.